Association Between SARS-CoV-2 Viral Load and COVID-19 Vaccination in 4 Phase 3 Trials.
Saved in:
| Title: | Association Between SARS-CoV-2 Viral Load and COVID-19 Vaccination in 4 Phase 3 Trials. |
|---|---|
| Authors: | Janes H; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Fisher LH; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Kee JJ; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Parameswaran L; New York University Langone Vaccine Center, New York University Grossman School of Medicine, New York, New York, USA., Goepfert PA; Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA., Falsey AR; Infectious Disease Division, University of Rochester, Rochester, New York, USA., Ludwig J; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Magaret CA; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Gilbert PB; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Kublin JG; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Rouphael N; Hope Clinic, Emory University, Atlanta, Georgia, USA., Sobieszczyk ME; Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA., El Sahly HM; Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA., Baden LR; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA., Grinsztejn B; Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil., Walsh SR; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA., Gray GE; South African Medical Research Council, Cape Town, South Africa., Kotloff KL; Department of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA., Gay CL; Division of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA., Greninger AL; Department of Medicine, Laboratory Medicine and Pathology, University of Washington Medical Center, Seattle, Washington, USA., Tapia MD; Department of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA., Hammershaimb EA; Department of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA., Priddy FH; Moderna, Inc, Cambridge, Massachusetts, USA., Green JA; Vaccines and Immune Therapies, BioPharmaceuticals Research and Development, AstraZeneca, Cambridge, United Kingdom., Struyf F; Janssen Research and Development, Beerse, Belgium., Dunkle L; Novavax, Inc, Gaithersburg, Maryland, USA., Neuzil KM; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA., Corey L; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Huang Y; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA. |
| Source: | The Journal of infectious diseases [J Infect Dis] 2024 Dec 16; Vol. 230 (6), pp. 1384-1389. |
| Publication Type: | Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial |
| Journal Info: | Publisher: Oxford University Press Country of Publication: United States NLM ID: 0413675 Publication Model: Print Cited Medium: Internet ISSN: 1537-6613 (Electronic) Linking ISSN: 00221899 NLM ISO Abbreviation: J Infect Dis Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
